CN1732952B - Compound dispersible tablet for treating hypertension - Google Patents
Compound dispersible tablet for treating hypertension Download PDFInfo
- Publication number
- CN1732952B CN1732952B CN 200510097975 CN200510097975A CN1732952B CN 1732952 B CN1732952 B CN 1732952B CN 200510097975 CN200510097975 CN 200510097975 CN 200510097975 A CN200510097975 A CN 200510097975A CN 1732952 B CN1732952 B CN 1732952B
- Authority
- CN
- China
- Prior art keywords
- valsartan
- hydrochlorothiazide
- disintegrating agent
- dispersible tablet
- lubricant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000007919 dispersible tablet Substances 0.000 title claims abstract description 17
- 150000001875 compounds Chemical class 0.000 title description 3
- 206010020772 Hypertension Diseases 0.000 title 1
- UIYUUEDFAMZISF-FTBISJDPSA-N 6-chloro-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide;(2s)-3-methyl-2-[pentanoyl-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O.C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NNN=N1 UIYUUEDFAMZISF-FTBISJDPSA-N 0.000 claims abstract description 33
- 239000003795 chemical substances by application Substances 0.000 claims description 21
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 17
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims description 16
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims description 16
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims description 16
- 229960004699 valsartan Drugs 0.000 claims description 16
- 229960002003 hydrochlorothiazide Drugs 0.000 claims description 15
- 239000000741 silica gel Substances 0.000 claims description 15
- 229910002027 silica gel Inorganic materials 0.000 claims description 15
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 14
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 13
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 13
- 229930195725 Mannitol Natural products 0.000 claims description 13
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 13
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 13
- 239000000594 mannitol Substances 0.000 claims description 13
- 235000010355 mannitol Nutrition 0.000 claims description 13
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 13
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 13
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 13
- 239000011734 sodium Substances 0.000 claims description 13
- 229910052708 sodium Inorganic materials 0.000 claims description 13
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 12
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 9
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 9
- 229960001855 mannitol Drugs 0.000 claims description 8
- 239000000945 filler Substances 0.000 claims description 7
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 7
- 229920000053 polysorbate 80 Polymers 0.000 claims description 7
- 239000000314 lubricant Substances 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 4
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 3
- 159000000007 calcium salts Chemical class 0.000 claims description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 3
- 229950005770 hyprolose Drugs 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 238000002360 preparation method Methods 0.000 abstract description 18
- 230000009286 beneficial effect Effects 0.000 abstract description 4
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 23
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 239000002671 adjuvant Substances 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 239000008187 granular material Substances 0.000 description 9
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 7
- 238000004090 dissolution Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000012856 packing Methods 0.000 description 7
- 238000005303 weighing Methods 0.000 description 7
- 206010013786 Dry skin Diseases 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 230000001476 alcoholic effect Effects 0.000 description 6
- 239000011230 binding agent Substances 0.000 description 6
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 6
- 239000000470 constituent Substances 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 6
- 229960003943 hypromellose Drugs 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000007779 soft material Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 108010011485 Aspartame Proteins 0.000 description 5
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 5
- 235000010357 aspartame Nutrition 0.000 description 5
- 239000000605 aspartame Substances 0.000 description 5
- 229960003438 aspartame Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 229940095672 calcium sulfate Drugs 0.000 description 4
- 229940082195 hydrochlorothiazide 12.5 mg Drugs 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 235000011132 calcium sulphate Nutrition 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 229940082205 hydrochlorothiazide 25 mg Drugs 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 229940102034 valsartan 80 mg Drugs 0.000 description 3
- -1 valsartan and hydrochlorothiazide compound Chemical class 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- 101800000733 Angiotensin-2 Proteins 0.000 description 2
- 102400000345 Angiotensin-2 Human genes 0.000 description 2
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229950006323 angiotensin ii Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007916 tablet composition Substances 0.000 description 2
- 229940102035 valsartan 160 mg Drugs 0.000 description 2
- 229940030337 valsartan 320 mg Drugs 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- 101150059573 AGTR1 gene Proteins 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000013409 condiments Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000005555 hypertensive agent Substances 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000011003 system suitability test Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a medicinal oral preparation containing Valsartan and Hydrochlorothiazide, more specifically the dispersible tablets for enhancing the beneficial effects of Valsartan and Hydrochlorothiazide.
Description
Technical field
The present invention relates to comprise the drug oral preparation of valsartan and hydrochlorothiazide, specifically relate to strengthen the tablet formulation of valsartan and hydrochlorothiazide beneficial effect.
Background technology
Valsartan is Angiotensin II (Angiotensin II) acceptor inhibitor, can suppress Ang I and be converted into Ang II, enzyme 1 receptor (AT1) of the nervous element conversion of antagonizing vessel specifically, to the antagonism of AT1 doubly greater than AT28500, by optionally blocking combining of Ang II and AT1 receptor, suppress the release of vasoconstriction and aldosterone, produce hypotensive effect.(hydrochlorothiazide is a kind of traditional antihypertensive drug HCTZ) to hydrochlorothiazide, imitates diuretic in belonging to.Act on distal renal tubular, activate renin-angiotensin system (RAS).The two use in conjunction can make blood pressure obtain more efficiently control; With respect to single preparations of ephedrine, the dose of every kind of medicine reduces, and the incidence rate of adverse effect also reduces accordingly, and simultaneously, valsartan can suppress owing to taking patient's blood potassium reduction that hydrochlorothiazide causes; And patient takes more conveniently, improves patient's compliance.So valsartan and hydrochlorothiazide compound preparation, because long action time, many advantages such as curative effect is good, and side effect is little become the first-selected medication of hyperpietic day by day.Oral and be its first-selected route of administration through gastrointestinal absorption, peroral dosage forms such as existing at present tablet, capsule.
Behind oral valsartan and the hydrochlorothiazide, blood drug level peaking about 2-4 hour, this mainly is because the inherent character of above-mentioned two kinds of principal agent compositions self determines.Those skilled in the art know, and solid preparation need experience the process of disintegrate, stripping, absorption, and performance is very disadvantageous for effectiveness of insoluble drug for this, thus ordinary preparation this be difficult to satisfy the hyperpietic to the urgent needs of relief of symptoms as early as possible.Therefore, develop valsartan and the hydrochlorothiazide oral formulations that to bring into play therapeutical effect, suitable more extensive crowd's use fast and become the technical problem that those skilled in the art face.
Therefore, those skilled in the art are readily appreciated that, also wish to develop the compound quick-acting preparation of valsartan and hydrochlorothiazide urgently, and it is the beneficial effect of onset and enhanced activity composition rapidly, and can be easily, without any administration with not accommodating any misgivings.Adopt mobile powerful adjuvant to carry out the technology of dry powder direct tabletting or employing dry granulation, though can directly realize preparation, but production cost is raise, this on the other hand technology is not general with respect to wet granulation technique, is unfavorable for generally using in wider scope.
Seemingly a kind of technical scheme that addresses the above problem of tablet formulation.Yet up to now, nobody provides the foundation of science to the development of valsartan and hydrochlorothiazide dosage form.
Summary of the invention
The object of the invention has provided a kind of dispersible tablet, comprises that the valsartan for the treatment of effective dose and hydrochlorothiazide are as active component.
As mentioned above, valsartan and hydrochlorothiazide all belong to insoluble drug.Therefore, at first will provide the compositions that is suitable for preparing dispersible tablet, said composition should be stable and not reduce the bioavailability of active component, even improve the bioavailability of active component significantly.
In pilot test, the inventor makes the dispersible tablet of valsartan and hydrochlorothiazide by the normal preparation dispersible tablet prescription that adopts of those skilled in the art, find under study for action: adopt the most frequently used lactose to be unfavorable for improving stability of formulation, on the one hand, be in a kind of labile state owing to the water of crystallization that contains in the lactose makes the principal agent composition, and easily in the preparation put procedure moisture absorption further disturb stability of formulation; On the other hand, the moisture absorption can influence preparation outward appearance, cause effective ingredient migration, though can be improved, under the situation of environmental abnormality, still be difficult to guarantee the quality of the pharmaceutical preparations, and can cause the increase of pharmaceutical production cost by strengthening packing.Nor be beneficial to the hyperpietic's who suffers from diabetes use; Short disintegrating agent-polyvinylpyrrolidone that another is commonly used also should not use in the present invention, can cause the dissolution of the long-term test specimen of placing to descend.
We have carried out deep research to the physicochemical property of valsartan and hydrochlorothiazide, particularly by screening, prescription and long-term investigation to adjuvant, address the above problem effectively, and the present invention has promptly been finished in further research on this basis.Compare with existing oral solid formulation, the quality of the pharmaceutical preparations of the present invention is stablized the rapid peaking of oral back blood drug level, and relative bioavailability significantly improves, and this effect is that those skilled in the art are unpredictable.
Valsartan and hydrochlorothiazide are all insoluble in water, adopt its dissolution of adjuvant of general aspects generally on the low side, and perhaps dissolution decline appears in the prolongation along with standing time.Its hydrophobicity should be emphasized to improve on the one hand, the hydrophilicity condiment that helps improving valsartan and hydrochlorothiazide stripping need be added on the other hand.Described adjuvant is selected from: mannitol, microcrystalline Cellulose, hyprolose, hydroxypropyl emthylcellulose, various anhydrous calcium salts.Preferably: mannitol, microcrystalline Cellulose, calcium sulfate, calcium phosphate dibasic anhydrous.
Cause the preparation disintegration time long at conventional tablet and the employed adjuvant of capsule, select compound disintegrating agent on the one hand, take the inside and outside method that adds to be improved on the other hand.Described disintegrating agent comprises disintegrating agent and short disintegrating agent, and wherein disintegrating agent is selected from: carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose; Short disintegrating agent is selected from: a kind of in sodium lauryl sulphate, dodecyl sodium sulfate, the tween 80 or their mixing.Preferred tween 80, sodium lauryl sulphate.
At valsartan and all relatively more sticking characteristic of hydrochlorothiazide, the inventor has strengthened the screening operation of wetting agent.Result of the test shows: the selection of wetting agent should be improved under the condition that a large amount of ethanol exist, and meets water viscosity and can't granulate too by force to prevent valsartan and hydrochlorothiazide, perhaps prolongs disintegration time; In ethanol, add simultaneously material,, can improve the uniformity of preparation under dispersity simultaneously to such an extent as to not only can avoid the soft tabletting that is difficult to of granule that uses ethanol to cause in a large number as cellulose family.
By our the surprised discovery of a large amount of screening tests: micropowder silica gel and talcous compositions are satisfactory for result as lubricant.Not only guarantee quick disintegrate, and very helpful to improving dissolution.
To further make non restrictive description below to the present invention.
Active component
By valsartan and hydrochlorothiazide weight, every contains valsartan 10～500mg, preferred 40-320mg, more preferably 80-160mg; Every contains hydrochlorothiazide 5～50mg, preferred 10～25mg.For the more effective dissolution rate that improves preparation that reaches, more advantageously active component is carried out pretreatment, it is crushed to more than 100 orders, more than preferred 120 orders, even micronization.
Filler
If active component (valsartan and hydrochlorothiazide weight sum) is by 1 part of calculating, then
Filler is 0.05～10 part, and is preferred: 0.1～5 part, and more preferably 0.2～3 part.Be selected from: mannitol, microcrystalline Cellulose, hyprolose, various anhydrous calcium salt.Preferably: mannitol, microcrystalline Cellulose, calcium sulfate, calcium phosphate dibasic anhydrous.
Disintegrating agent: comprise disintegrating agent and short disintegrating agent
Disintegrating agent is 0.01～1 part, and is preferred: 0.03～0.5 part, and more preferably 0.05～0.3 part.Be selected from: carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose.
Short disintegrating agent is 0.001～0.5 part, and is preferred: 0.01～0.3 part, and more preferably 0.02～0.2 part.Be selected from: a kind of in sodium lauryl sulphate, dodecyl sodium sulfate, the Tween 80 or their mixing.Preferred tween 80, sodium lauryl sulphate.
Lubricant is 0.001～0.5 part, 0.01～0.3 part, and more preferably 0.02～0.2 part.Be selected from: micropowder silica gel and Pulvis Talci.
We are surprised to find, and add above-mentioned adjuvant when preparation dispersible tablet of the present invention, not only make this dispersible tablet stable, but also disintegrate are rapid, and are rapid-action.Result of the test shows, the unfavorable phenomenon of degradation under prolonged disintegration, the stripping do not occur after the long-term placement of described dispersible tablet, and this is to keeping bioavailability of medicament very favourable.Can think that thus preparation of the present invention also has stable, the advantage that significantly improves of peaking and bioavailability rapidly of active component except the characteristics that have dispersible tablet formulation itself and had.
Other adjuvants
Advantageously, for making the more stable and each side of dispersible tablet sensation better, the present invention also can choose further adding correctives, for example aspartame, steviosin, protein sugar etc. wantonly.
Thus, the invention provides a kind of dispersible tablet that contains valsartan and hydrochlorothiazide, comprising:
A. by valsartan and hydrochlorothiazide weight, every contains valsartan 50～500mg, preferred 80-160mg; Every contains hydrochlorothiazide 5～50mg, preferred 10～25mg.
B. by 1 part, then adjuvant content is 0.05～15 part as if active component (valsartan and hydrochlorothiazide weight sum).Preferred 0.2～7 part, more excellent 0.3～4 part.
Above-mentioned adjuvant comprises filler, disintegrating agent, short disintegrating agent, lubricant, wetting agent.
The present invention does not make specific limited to the preparation method of dispersible tablet, can adopt this area conventional method, for example wet granulation.Described dispersible tablet face shaping is not made specific limited, can be existing arbitrary shape.
Following examples are intended to further specify the present invention, scope of the present invention are not limited.Those skilled in the art can not depart from the improvement and the variation of category of the present invention and spirit to embodiment disclosed herein.
Specific embodiments
Embodiment 1: prescription (calculating with monolithic)
Constituent content (mg/ sheet)
Valsartan 320mg
Hydrochlorothiazide 12.5mg
Microcrystalline Cellulose 150mg
Mannitol 100mg
Carboxymethyl starch sodium 40mg
Low-substituted hydroxypropyl cellulose 10mg
Micropowder silica gel 10mg
Pulvis Talci 5mg
Steviosin 5mg
90% alcoholic solution of 3% hypromellose is an amount of
Sheet heavily amounts to 652.5mg
Technology:
Get valsartan and hydrochlorothiazide raw material, pulverize, behind 200 mesh sieves, standby excessively.
Press recipe quantity, take by weighing valsartan and hydrochlorothiazide, microcrystalline Cellulose, mannitol, steviosin and carboxymethylstach sodium and cross 100 mesh sieve mix homogeneously, pour binding agent system soft material into, cross 40 mesh sieves and granulate 55 ℃ of dryings, 40 order granulate, adding is through low-substituted hydroxypropyl cellulose, micropowder silica gel, the Pulvis Talci of 100 mesh sieves, mix homogeneously detects, and adjustment sheet is heavy, tabletting, check, packing, promptly.
Embodiment 2: prescription (calculating with monolithic)
Constituent content (mg/ sheet)
Valsartan 80mg
Hydrochlorothiazide 25mg
Calcium sulfate 50mg
Microcrystalline Cellulose 100mg
Low-substituted hydroxypropyl cellulose 30mg
Micropowder silica gel 5mg
Pulvis Talci 5mg
Aspartame 5mg
75% alcoholic solution of 2% hypromellose is an amount of
Sheet heavily amounts to 300mg
Technology:
Press recipe quantity, take by weighing the low-substituted hydroxypropyl cellulose of valsartan and hydrochlorothiazide, calcium sulfate, microcrystalline Cellulose, aspartame and recipe quantity 3/4, cross 100 mesh sieve mix homogeneously, the binding agent system of pouring into soft material is crossed 20 mesh sieves and is granulated 50 ℃ of dryings, 20 order granulate add micropowder silica gel, Pulvis Talci and residue low-substituted hydroxypropyl cellulose through 100 mesh sieves, mix homogeneously, detect, adjustment sheet is heavy, tabletting, check, packing, promptly.
Embodiment 3: prescription (calculating with monolithic)
Constituent content (mg/ sheet)
Valsartan 320mg
Hydrochlorothiazide 25mg
Mannitol 75mg
Calcium sulfate 75mg
Carboxymethylstach sodium 50mg
Low-substituted hydroxypropyl cellulose 10mg
Sodium lauryl sulphate 15mg
Micropowder silica gel 10mg
Pulvis Talci 10mg
Protein sugar 20mg
95% alcoholic solution of 5% hypromellose is an amount of
Sheet heavily amounts to 610mg
Technology:
Get valsartan and hydrochlorothiazide raw material, pulverize, behind 180 mesh sieves, standby excessively.
Press recipe quantity, take by weighing valsartan and hydrochlorothiazide, mannitol, calcium sulfate, carboxymethylstach sodium, sodium lauryl sulphate, protein sugar, cross 100 mesh sieve mix homogeneously, the binding agent system of pouring into soft material is crossed 18 mesh sieves and is granulated 60 ℃ of dryings, 20 order granulate add micropowder silica gel, Pulvis Talci and low-substituted hydroxypropyl cellulose through 100 mesh sieves, mix homogeneously, detect, adjustment sheet is heavy, tabletting, check, packing, promptly.
Embodiment 4: prescription (calculating with monolithic)
Constituent content (mg/ sheet)
Valsartan 80mg
Hydrochlorothiazide 12.5mg
Calcium phosphate dibasic anhydrous 150mg
Microcrystalline Cellulose 200mg
Carboxymethylstach sodium 50mg
Micropowder silica gel 5mg
Pulvis Talci 5mg
Steviosin 3mg
70% alcoholic solution of 1% hypromellose is an amount of
Sheet heavily amounts to 505.5mg
Technology:
Press recipe quantity, take by weighing valsartan and hydrochlorothiazide, calcium phosphate dibasic anhydrous, microcrystalline Cellulose, 3/4 carboxymethylstach sodium, micropowder silica gel, steviosin, cross 100 mesh sieve mix homogeneously, the binding agent system of pouring into soft material is crossed 24 mesh sieves, 55 ℃ of dryings, 24 order granulate add Pulvis Talci and remaining carboxymethylstach sodium, mix homogeneously, detect, adjustment sheet is heavy, tabletting, check, packing, promptly.
Embodiment 5: prescription (calculating with monolithic)
Constituent content (mg/ sheet)
Valsartan 160mg
Hydrochlorothiazide 12.5mg
Calcium phosphate dibasic anhydrous 50mg
Mannitol 100mg
Low-substituted hydroxypropyl cellulose 20mg
Tween 80 3mg
Micropowder silica gel 5mg
Pulvis Talci 2mg
Aspartame 3mg
75% alcoholic solution of 3% hypromellose is an amount of
Sheet heavily amounts to 355.5mg
Technology:
Get valsartan and hydrochlorothiazide raw material, pulverize, behind 120 mesh sieves, standby excessively.
Press recipe quantity, take by weighing valsartan and hydrochlorothiazide, calcium phosphate dibasic anhydrous, 3/4 low-substituted hydroxypropyl cellulose, mannitol, micropowder silica gel, aspartame, cross 100 sieve mix homogeneously, pour binding agent and tween 80 system soft material into, cross 40 mesh sieves, 55 ℃ of dryings, 40 order granulate add Pulvis Talci and remaining low-substituted hydroxypropyl cellulose, mix homogeneously, detect, adjustment sheet is heavy, tabletting, check, packing, promptly.
Embodiment 6: prescription (calculating with monolithic)
Constituent content (mg/ sheet)
Valsartan 160mg
Hydrochlorothiazide 25mg
Microcrystalline Cellulose 120mg
Mannitol 100mg
Carboxymethylstach sodium 40mg
Sodium lauryl sulphate 5mg
Micropowder silica gel 5mg
Pulvis Talci 2mg
Steviosin 5mg
90% alcoholic solution of 2% hypromellose is an amount of
Sheet heavily amounts to 462mg
Technology:
Get valsartan and hydrochlorothiazide raw material, pulverize, behind 140 mesh sieves, standby excessively.
Press recipe quantity, take by weighing valsartan and hydrochlorothiazide, microcrystalline Cellulose, mannitol, 3/4 carboxymethylstach sodium, sodium lauryl sulphate, steviosin, cross 100 mesh sieve mix homogeneously, the binding agent system of pouring into soft material is crossed 40 mesh sieves, 55 ℃ of dryings, 40 order granulate add micropowder silica gel, Pulvis Talci and remaining carboxymethylstach sodium, mix homogeneously, detect, adjustment sheet is heavy, tabletting, check, packing, promptly.
Comparative test 1: dissolution in vitro experiment
Chromatographic condition and system suitability test: with octadecylsilane chemically bonded silica is filler; Transferring PH=2.5 with water-acetonitrile (1: 1) with phosphoric acid is mobile phase; Detect wavelength 272nm; Flow velocity is 0.8mL/min; Number of theoretical plate calculates by the valsartan peak should be not less than 1500
Dissolution determination method: get each test specimen, according to dissolution method (two appendix XC first methods of Chinese Pharmacopoeia version in 2000), 900mL is a solvent with pH6.8 phosphate buffer (get 6.8g potassium dihydrogen phosphate and 0.9g sodium hydroxide, add water 1000mL, shake up), rotating speed is that per minute 100 changes, operation in the time of 15 minutes, is got solution 5mL in accordance with the law, filter, get subsequent filtrate and make need testing solution; In addition precision takes by weighing valsartan respectively, the hydrochlorothiazide reference substance is an amount of, makes the valsartan that contains 80 μ g/mL approximately and the hydrochlorothiazide reference substance solution of 12.5 μ g/mL.According to above-mentioned chromatographic condition, sample introduction, record chromatogram; Go out every stripping quantity with calculated by peak area by external standard method.
Testing result such as following table
The dispersible tablet test specimen of different prescriptions, stripping quantity has reached more than 80% of labelled amount in the time of 5 minutes, and stripping quantity is near more than 100% of labelled amount in the time of 15 minutes; And the stripping in 5 minutes of valsartan and hydrochlorothiazide ordinary tablet when just just having reached 50%, 30 minute stripping just near fully, the two significant difference.
Comparative test 2 bioavailability
With rp-hplc valsartan and hydrochlorothiazide blood drug level, calculate relevant pharmacokinetic parameter with 3P87 pharmacokinetics program, its main pharmacokinetic parameter is through three-factor analysis of variance, intersect oral valsartan and hydrochlorothiazide (valsartan 80mg and hydrochlorothiazide 12.5mg) at random, the valsartan and Hydrochlorothiade ordinary tablet of selecting respectively to sell on example 4 samples and the market is tested, and the relative bioavailability of the two is estimated.The result shows, preparation of the present invention significantly improves in the body and absorbs, and significantly improves bioavailability, significantly is better than existing conventional tablet.
Table 1: comparative test result
Claims (2)
1. the dispersible tablet of valsartan and hydrochlorothiazide, form by valsartan, hydrochlorothiazide and the pharmaceutic adjuvant of treatment effective dose:
A. by valsartan and hydrochlorothiazide, every contains valsartan 10～500mg, and every contains hydrochlorothiazide 5～50mg;
B. pharmaceutic adjuvant comprises filler, disintegrating agent, short disintegrating agent, lubricant,
Filler is selected from: mannitol, microcrystalline Cellulose, hyprolose, various anhydrous calcium salt;
Disintegrating agent is selected from: carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose;
Short disintegrating agent is selected from: a kind of in sodium lauryl sulphate, dodecyl sodium sulfate, the Tween 80 or their mixing;
Lubricant is selected from: micropowder silica gel and Pulvis Talci;
Wherein valsartan and hydrochlorothiazide weight sum is by 1 part,
Filler is 0.05～10 part;
Disintegrating agent is 0.01～1 part;
Short disintegrating agent is 0.001～0.5 part;
Lubricant is 0.001～0.5 part.
2. the dispersible tablet of valsartan according to claim 1 and hydrochlorothiazide is characterized in that:
Wherein contain valsartan 80-160mg, hydrochlorothiazide 12.5～25mg in every.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510097975 CN1732952B (en) | 2005-09-02 | 2005-09-02 | Compound dispersible tablet for treating hypertension |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510097975 CN1732952B (en) | 2005-09-02 | 2005-09-02 | Compound dispersible tablet for treating hypertension |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1732952A CN1732952A (en) | 2006-02-15 |
| CN1732952B true CN1732952B (en) | 2010-04-07 |
Family
ID=36075708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510097975 Active CN1732952B (en) | 2005-09-02 | 2005-09-02 | Compound dispersible tablet for treating hypertension |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1732952B (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101972263B (en) * | 2010-09-13 | 2012-01-11 | 海南美兰史克制药有限公司 | Valsartan hydrochlorothiazide pharmaceutical composition liposome solid preparation |
| WO2013098576A1 (en) * | 2011-12-31 | 2013-07-04 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Immediate release pharmaceutical composition of valsartan |
| WO2013098578A1 (en) * | 2011-12-31 | 2013-07-04 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Immediate release pharmaceutical composition of valsartan hydrochlorothiazide |
| CN102631357B (en) * | 2012-04-13 | 2013-04-17 | 重庆康刻尔制药有限公司 | Composite tablet of valsartan and hydrochlorothiazide and preparation method thereof |
| CN103191125B (en) * | 2013-04-19 | 2014-12-24 | 北京费森尤斯卡比医药有限公司 | Valsartan and hydrochlorothiazid tablet and preparation method thereof |
| CN103494822B (en) * | 2013-07-22 | 2016-06-22 | 广东工业大学 | A kind of compound anti-cancer medicine combining Statins pravastatin and thiazide antihypertensive drug |
| CN103720696B (en) * | 2013-12-27 | 2016-03-30 | 辰欣药业股份有限公司 | A kind of preparation technology improving valsartan and Hydrochlorothiade capsule bioavailability |
| CN104274468A (en) * | 2014-10-11 | 2015-01-14 | 江西施美制药有限公司 | Valsartan/hydrochlorothiazide pharmaceutical composition and preparation method thereof |
| CN106619618B (en) * | 2016-12-28 | 2019-12-13 | 华润赛科药业有限责任公司 | valsartan pharmaceutical composition and preparation method thereof |
| CN106983752B (en) * | 2017-04-01 | 2020-07-10 | 重庆康刻尔制药有限公司 | Preparation method of valsartan and hydrochlorothiazide capsules |
| WO2023128902A1 (en) * | 2021-12-30 | 2023-07-06 | Pharmactive Ilac Sanayi Ve Ticaret A.S. | Pharmaceutical compositions comprising bosentan and relevant excipients |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1474690A (en) * | 2000-11-17 | 2004-02-11 | ��˹��ŵ�� | Synergestic combinations comprising renin inhibitor for cardiovascular diseases |
| CN1565448A (en) * | 2003-06-16 | 2005-01-19 | 河北赛克药业有限公司 | Nitrendipine dispersion tablet and method for making same |
-
2005
- 2005-09-02 CN CN 200510097975 patent/CN1732952B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1474690A (en) * | 2000-11-17 | 2004-02-11 | ��˹��ŵ�� | Synergestic combinations comprising renin inhibitor for cardiovascular diseases |
| CN1565448A (en) * | 2003-06-16 | 2005-01-19 | 河北赛克药业有限公司 | Nitrendipine dispersion tablet and method for making same |
Non-Patent Citations (2)
| Title |
|---|
| 张志华等.缬沙坦分散片与胶囊在健康人体的相对生物利用度研究.中南药学2 6.2004,2(6),333-334. * |
| 黄建耿等.复方缬沙坦分散片在健康人体内的药物动力学.中国医药工业杂志38 11.2007,38(11),780-783. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1732952A (en) | 2006-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5295123B2 (en) | New pharmaceutical composition | |
| CN102085201B (en) | Atenolol and amlodipine bilayer tablet | |
| TW200948358A (en) | Dissolution improved pharmaceutical composition comprising olmesartan medoxomil | |
| CN1732952B (en) | Compound dispersible tablet for treating hypertension | |
| CN109875972B (en) | Olmesartan medoxomil and amlodipine pharmaceutical composition | |
| TW200835526A (en) | Solid dosage form | |
| TWI414310B (en) | Elution-improved pharmaceutical preparation | |
| CN109481437B (en) | Losartan potassium pharmaceutical preparation | |
| WO2008101375A1 (en) | A gastric retentive sustained-release pharmaceutical composition comprising irbesartan | |
| CN100577157C (en) | Dispersant tablet containing hypolipidemic component and preparation method thereof | |
| CN103505460B (en) | A kind of method preparing losartan potassium hydrochlorothiazide composition | |
| CN1732953B (en) | Dispersible tablet for treating hypertension | |
| CN102058872A (en) | Medicinal composition containing Lysinopril and amlodipine besilate and preparation method thereof | |
| CN103860511A (en) | Pharmaceutical composition containing irbesartan and amlodipine benzenesulfonate and preparation method thereof | |
| TW200835525A (en) | Method for improvement of elution | |
| CN109394712B (en) | A kind of valsartan amlodipine composite tablet and preparation method thereof | |
| CN100421662C (en) | Disperese torasemide tablet and its prepn and application | |
| CN100455288C (en) | Formula of Reynoldazine hydrochloride prepn. | |
| CN103705513B (en) | A kind of pharmaceutical composition containing candesartan Cilexetil and Amlodipine Besylate Tablet and preparation method thereof | |
| WO2024160220A1 (en) | Brivaracetam double-release three-layer tablet and preparation method therefor | |
| CN113226315B (en) | Pharmaceutical composition containing kidney potassium ion efflux channel inhibitor and preparation method thereof | |
| CN101904828B (en) | Metoprolol controlled release mixed matrix tablet and preparation method thereof | |
| WO2024109927A1 (en) | Pharmaceutical composition comprising azilsartan medoxomil potassium and calcium channel blocker, method for preparing same, and use thereof | |
| KR101944085B1 (en) | Solid oral dosage form containing valsartan, and preparation method therefor | |
| CN101461814A (en) | Medicament composition containing losartan and hydrochlorothiazidum |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Hainan Aomei Pharmaceutical Co. Ltd. Assignor: Yao Junhua Contract record no.: 2011320000887 Denomination of invention: Compound dispersible tablet for treating hypertension Granted publication date: 20100407 License type: Exclusive License Open date: 20060215 Record date: 20110624 |
|
| ASS | Succession or assignment of patent right |
Owner name: JIANGSU VANGUARD PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: YAO JUNHUA Effective date: 20120307 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20120307 Address after: 226100 Jiangsu Province Haimen Economic Development Zone Dinghai Road No. 688 Patentee after: Jiaosu Wangao Pharmaceutical Co., Ltd. Address before: 226100 Jiangsu Province Haimen Economic Development Zone Dinghai Road No. 688 Patentee before: Yao Junhua |
|
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 226100 Jiangsu Province Haimen Economic Development Zone Dinghai Road No. 688 Patentee after: Jiangsu Wangao Pharmaceutical Co., Ltd. Address before: 226100 Jiangsu Province Haimen Economic Development Zone Dinghai Road No. 688 Patentee before: Jiaosu Wangao Pharmaceutical Co., Ltd. |